| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GILD - Guild Esports Plc | HOLD | 0 @ USD 104.54 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 104.54. The average price that GILD shares were previous bought at was USD 105.254. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in GILD has fallen by USD 113,120 compared to the previous valuation of Guild Esports Plc |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 489.1 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 489.1. The average price that VRTX shares were previous bought at was USD 470.792. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 254,454 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 277.29 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 277.29. The average price that AMGN shares were previous bought at was USD 275.864. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 660,474 compared to the previous valuation of Amgen Inc |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 563.16 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 563.16. The average price that REGN shares were previous bought at was USD 690.459. The current market price is -18.4% lower than average price they were purchased at. The value of the holding in REGN has increased by USD 707,783 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 67.59 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 67.59. The average price that AZN shares were previous bought at was USD 73.8309. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in AZN has increased by USD 149,137 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 234.56 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 234.56. The average price that ALNY shares were previous bought at was USD 269.305. The current market price is -12.9% lower than average price they were purchased at. The value of the holding in ALNY has increased by USD 249,263 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 118.61 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 118.61. The average price that BIIB shares were previous bought at was USD 139.08. The current market price is -14.7% lower than average price they were purchased at. The value of the holding in BIIB has increased by USD 230,488 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 71.2 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 71.2. The average price that ILMN shares were previous bought at was USD 90.3238. The current market price is -21.2% lower than average price they were purchased at. The value of the holding in ILMN has fallen by USD 175,067 compared to the previous valuation of Illumina Inc |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 596.2 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 596.2. The average price that ARGX shares were previous bought at was USD 608.988. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in ARGX has increased by USD 130,717 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 284.73 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 284.73. The average price that UTHR shares were previous bought at was USD 326.536. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in UTHR has fallen by USD 9,796 compared to the previous valuation of United Therapeutics Corporation |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.715 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.715. The average price that MRNA shares were previous bought at was USD 31.7186. The current market price is -22.1% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 86,931 compared to the previous valuation of Moderna Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 58.21 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 58.21. The average price that INCY shares were previous bought at was USD 64.4184. The current market price is -9.6% lower than average price they were purchased at. The value of the holding in INCY has increased by USD 44,066 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VTRS - Viatris Inc | HOLD | 0 @ USD 7.56 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 7.56. The average price that VTRS shares were previous bought at was USD 9.61349. The current market price is -21.4% lower than average price they were purchased at. The value of the holding in VTRS has increased by USD 96,261 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 24.61 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 24.61. The average price that SMMT shares were previous bought at was USD 19.4387. The current market price is 26.6% higher than average price they were purchased at. The value of the holding in SMMT has increased by USD 545,872 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 50.9 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 50.9. The average price that SNY shares were previous bought at was USD 54.2112. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in SNY has increased by USD 46,343 compared to the previous valuation of Sanofi ADR however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 101.38 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 101.38. The average price that NBIX shares were previous bought at was USD 113.067. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in NBIX has increased by USD 60,550 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 59.17 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 59.17. The average price that BMRN shares were previous bought at was USD 68.4387. The current market price is -13.5% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 31,671 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 72.65 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 72.65. The average price that INSM shares were previous bought at was USD 77.6662. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in INSM has increased by USD 210,362 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 32.6 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 32.6. The average price that RPRX shares were previous bought at was USD 32.3514. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 84,275 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 296.28 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 296.28. The average price that MEDP shares were previous bought at was USD 319.654. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in MEDP has fallen by USD 3,178 compared to the previous valuation of Medpace Holdings Inc |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 30.65 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 30.65. The average price that PCVX shares were previous bought at was USD 71.6956. The current market price is -57.2% lower than average price they were purchased at. The value of the holding in PCVX has increased by USD 93,481 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 53.79 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 53.79. The average price that SRPT shares were previous bought at was USD 82.0259. The current market price is -34.4% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 6,906 compared to the previous valuation of Sarepta Therapeutics Inc |
| BNTX - BioNTech SE | HOLD | 0 @ USD 98.76 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 98.76. The average price that BNTX shares were previous bought at was USD 100.416. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in BNTX has increased by USD 24,069 compared to the previous valuation of BioNTech SE however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 36.19 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 36.19. The average price that EXEL shares were previous bought at was USD 35.5146. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 5,310 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 36.76 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 36.76. The average price that RVMD shares were previous bought at was USD 37.9217. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in RVMD has increased by USD 49,393 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 10.15 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 10.15. The average price that ROIV shares were previous bought at was USD 10.4567. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in ROIV has increased by USD 44,007 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 102.78 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 102.78. The average price that JAZZ shares were previous bought at was USD 133.808. The current market price is -23.2% lower than average price they were purchased at. The value of the holding in JAZZ has increased by USD 35,436 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 58.79 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 58.79. The average price that HALO shares were previous bought at was USD 60.6498. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in HALO has fallen by USD 1,753 compared to the previous valuation of Halozyme Therapeutics Inc |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 165.05 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 165.05. The average price that ASND shares were previous bought at was USD 152.194. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in ASND has increased by USD 197,706 compared to the previous valuation of Ascendis Pharma AS however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 301.66 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 301.66. The average price that MDGL shares were previous bought at was USD 335.125. The current market price is -10.0% lower than average price they were purchased at. The value of the holding in MDGL has fallen by USD 64,077 compared to the previous valuation of Madrigal Pharmaceuticals Inc |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 39.48 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 39.48. The average price that CYTK shares were previous bought at was USD 42.442. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in CYTK has increased by USD 18,541 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BPMC - Blueprint Medicines Corp | HOLD | 0 @ USD 84.69 | USD 0 | The current share valuation price of BPMC based on adjusted close was USD 84.69. The average price that BPMC shares were previous bought at was USD 90.5769. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in BPMC has increased by USD 78,233 compared to the previous valuation of Blueprint Medicines Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 28.4 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 28.4. The average price that IONS shares were previous bought at was USD 30.9183. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in IONS has increased by USD 3,772 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 26.66 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 26.66. The average price that RNA shares were previous bought at was USD 30.2078. The current market price is -11.7% lower than average price they were purchased at. The value of the holding in RNA has increased by USD 51,333 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 62.02 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 62.02. The average price that ACLX shares were previous bought at was USD 67.5386. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in ACLX has increased by USD 34,683 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 71.64 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 71.64. The average price that NUVL shares were previous bought at was USD 77.3976. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in NUVL has increased by USD 52,428 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 168.57 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 168.57. The average price that KRYS shares were previous bought at was USD 174.956. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in KRYS has increased by USD 52,888 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 21.31 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 21.31. The average price that ADMA shares were previous bought at was USD 18.4914. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in ADMA has increased by USD 8,973 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 27 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 27. The average price that ALKS shares were previous bought at was USD 33.8462. The current market price is -20.2% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 15,432 compared to the previous valuation of Alkermes Plc |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 104.46 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 104.46. The average price that AXSM shares were previous bought at was USD 123.963. The current market price is -15.7% lower than average price they were purchased at. The value of the holding in AXSM has fallen by USD 231 compared to the previous valuation of Axsome Therapeutics Inc |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 30.42 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 30.42. The average price that CRNX shares were previous bought at was USD 37.7547. The current market price is -19.4% lower than average price they were purchased at. The value of the holding in CRNX has increased by USD 37,084 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 33.87 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 33.87. The average price that BBIO shares were previous bought at was USD 32.5318. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 1,805 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RARE - Ultragenyx | HOLD | 0 @ USD 35.69 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 35.69. The average price that RARE shares were previous bought at was USD 38.828. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in RARE has increased by USD 31,161 compared to the previous valuation of Ultragenyx however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 35.69 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 35.69. The average price that RARE shares were previous bought at was USD 38.828. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in RARE has increased by USD 31,161 compared to the previous valuation of WISETFWTMRARETFP however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 37.77 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 37.77. The average price that CRSP shares were previous bought at was USD 39.2853. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in CRSP has fallen by USD 407 compared to the previous valuation of Crispr Therapeutics AG |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 15.15 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 15.15. The average price that IMVT shares were previous bought at was USD 19.0562. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in IMVT has increased by USD 24,990 compared to the previous valuation of Immunovant Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 12.74 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 12.74. The average price that DNLI shares were previous bought at was USD 15.3662. The current market price is -17.1% lower than average price they were purchased at. The value of the holding in DNLI has increased by USD 13,190 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 61.74 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 61.74. The average price that RYTM shares were previous bought at was USD 52.5796. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 12,001 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 44.97 | USD 0 | The current share valuation price of GH based on adjusted close was USD 44.97. The average price that GH shares were previous bought at was USD 44.4694. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 12,298 compared to the previous valuation of Guardant Health Inc |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 18.2 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 18.2. The average price that APLS shares were previous bought at was USD 24.7773. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in APLS has increased by USD 2,385 compared to the previous valuation of Apellis Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 43.055 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 43.055. The average price that MRUS shares were previous bought at was USD 43.5066. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in MRUS has increased by USD 37,546 compared to the previous valuation of Merus BV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.47 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.47. The average price that IBRX shares were previous bought at was USD 3.09681. The current market price is -20.2% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 3,482 compared to the previous valuation of Immunitybio Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 47.39 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 47.39. The average price that PTCT shares were previous bought at was USD 52.7048. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in PTCT has increased by USD 36,679 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 27.66 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 27.66. The average price that AGIO shares were previous bought at was USD 30.5104. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in AGIO has increased by USD 14,299 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 13.45 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 13.45. The average price that EWTX shares were previous bought at was USD 23.1295. The current market price is -41.8% lower than average price they were purchased at. The value of the holding in EWTX has increased by USD 18,987 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 32.8 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 32.8. The average price that LEGN shares were previous bought at was USD 35.0227. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in LEGN has fallen by USD 25,606 compared to the previous valuation of Legend Biotech Corp |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 35.11 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 35.11. The average price that XENE shares were previous bought at was USD 35.7499. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in XENE has increased by USD 47,555 compared to the previous valuation of Xenon Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 25.97 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 25.97. The average price that KYMR shares were previous bought at was USD 30.7874. The current market price is -15.6% lower than average price they were purchased at. The value of the holding in KYMR has increased by USD 29,570 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 6.83 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 6.83. The average price that FOLD shares were previous bought at was USD 8.86289. The current market price is -22.9% lower than average price they were purchased at. The value of the holding in FOLD has increased by USD 19,001 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 14.73 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 14.73. The average price that ACAD shares were previous bought at was USD 17.3172. The current market price is -14.9% lower than average price they were purchased at. The value of the holding in ACAD has increased by USD 12,674 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 8.17 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 8.17. The average price that DYN shares were previous bought at was USD 12.1233. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in DYN has increased by USD 17,958 compared to the previous valuation of Dyne Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 8.17 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 8.17. The average price that DYN shares were previous bought at was USD 12.1233. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in DYN has increased by USD 17,958 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 3.06 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 3.06. The average price that IOVA shares were previous bought at was USD 3.85631. The current market price is -20.6% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 1,530 compared to the previous valuation of Iovance Biotherapeutics Inc |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 31.14 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 31.14. The average price that VCYT shares were previous bought at was USD 33.1234. The current market price is -6.0% lower than average price they were purchased at. The value of the holding in VCYT has fallen by USD 14,487 compared to the previous valuation of Veracyte Inc |
| VRNA - Verona Pharma PLC ADR | HOLD | 0 @ USD 58.92 | USD 0 | The current share valuation price of VRNA based on adjusted close was USD 58.92. The average price that VRNA shares were previous bought at was USD 64.2132. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in VRNA has increased by USD 23,181 compared to the previous valuation of Verona Pharma PLC ADR however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 29.69 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 29.69. The average price that JANX shares were previous bought at was USD 32.0121. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 28,410 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 41.23 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 41.23. The average price that VCEL shares were previous bought at was USD 47.8966. The current market price is -13.9% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 9,772 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 36.8 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 36.8. The average price that TWST shares were previous bought at was USD 42.5099. The current market price is -13.4% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 46,890 compared to the previous valuation of Twist Bioscience Corp |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 11.24 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 11.24. The average price that ARWR shares were previous bought at was USD 14.9749. The current market price is -24.9% lower than average price they were purchased at. The value of the holding in ARWR has fallen by USD 6,665 compared to the previous valuation of Arrowhead Pharmaceuticals Inc |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 21.29 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 21.29. The average price that VERA shares were previous bought at was USD 30.0977. The current market price is -29.3% lower than average price they were purchased at. The value of the holding in VERA has increased by USD 1,534 compared to the previous valuation of Vera Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 17.08 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 17.08. The average price that IDYA shares were previous bought at was USD 17.7885. The current market price is -4.0% lower than average price they were purchased at. The value of the holding in IDYA has increased by USD 37,981 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 33.11 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 33.11. The average price that APGE shares were previous bought at was USD 36.9712. The current market price is -10.4% lower than average price they were purchased at. The value of the holding in APGE has increased by USD 23,125 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 46.28 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 46.28. The average price that PTGX shares were previous bought at was USD 47.7196. The current market price is -3.0% lower than average price they were purchased at. The value of the holding in PTGX has increased by USD 13,982 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SWTX - SpringWorks Therapeutics Inc | HOLD | 0 @ USD 37.92 | USD 0 | The current share valuation price of SWTX based on adjusted close was USD 37.92. The average price that SWTX shares were previous bought at was USD 49.5894. The current market price is -23.5% lower than average price they were purchased at. The value of the holding in SWTX has increased by USD 6,401 compared to the previous valuation of SpringWorks Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 14.07 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 14.07. The average price that KROS shares were previous bought at was USD 10.1271. The current market price is 38.9% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 9,904 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.27 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.27. The average price that GERN shares were previous bought at was USD 1.98217. The current market price is -35.9% lower than average price they were purchased at. The value of the holding in GERN has increased by USD 8,918 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 23.35 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 23.35. The average price that AMPH shares were previous bought at was USD 29.2536. The current market price is -20.2% lower than average price they were purchased at. The value of the holding in AMPH has increased by USD 8,352 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 17 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 17. The average price that BEAM shares were previous bought at was USD 22.6226. The current market price is -24.9% lower than average price they were purchased at. The value of the holding in BEAM has increased by USD 15,271 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 37.63 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 37.63. The average price that AKRO shares were previous bought at was USD 44.8358. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in AKRO has increased by USD 7,180 compared to the previous valuation of Akero Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 104.97 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 104.97. The average price that LGND shares were previous bought at was USD 108.681. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in LGND has increased by USD 3,222 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 21.76 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 21.76. The average price that GPCR shares were previous bought at was USD 21.2142. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in GPCR has increased by USD 89,846 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 30.75 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 30.75. The average price that SRRK shares were previous bought at was USD 36.1933. The current market price is -15.0% lower than average price they were purchased at. The value of the holding in SRRK has increased by USD 44,477 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 30.76 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 30.76. The average price that SUPN shares were previous bought at was USD 33.8813. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in SUPN has increased by USD 1,304 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 5.5. The average price that RXRX shares were previous bought at was USD 6.34715. The current market price is -13.3% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 33,950 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 39.1 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 39.1. The average price that MIRM shares were previous bought at was USD 47.01. The current market price is -16.8% lower than average price they were purchased at. The value of the holding in MIRM has increased by USD 8,183 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 5.92 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 5.92. The average price that WVE shares were previous bought at was USD 10.7659. The current market price is -45.0% lower than average price they were purchased at. The value of the holding in WVE has increased by USD 5,911 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 28.46 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 28.46. The average price that HRMY shares were previous bought at was USD 35.7658. The current market price is -20.4% lower than average price they were purchased at. The value of the holding in HRMY has increased by USD 13,929 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 5.29001 | USD 0 | |
| MNKD - MannKind Corp | HOLD | 0 @ USD 4.54 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 4.54. The average price that MNKD shares were previous bought at was USD 5.42772. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in MNKD has increased by USD 1,461 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 15.58 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 15.58. The average price that NVCR shares were previous bought at was USD 19.6925. The current market price is -20.9% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 12,836 compared to the previous valuation of Novocure Ltd |
| IRON - Ironveld Plc | HOLD | 0 @ USD 42.165 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 42.165. The average price that IRON shares were previous bought at was USD 51.5823. The current market price is -18.3% lower than average price they were purchased at. The value of the holding in IRON has increased by USD 19,320 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 8.6 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 8.6. The average price that ARVN shares were previous bought at was USD 10.7551. The current market price is -20.0% lower than average price they were purchased at. The value of the holding in ARVN has increased by USD 31,654 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 49.25 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 49.25. The average price that TARS shares were previous bought at was USD 49.544. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in TARS has fallen by USD 2,570 compared to the previous valuation of Tarsus Pharmaceuticals Inc |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.31 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.31. The average price that DVAX shares were previous bought at was USD 12.7839. The current market price is -19.4% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 19,952 compared to the previous valuation of Dynavax Technologies Corporation |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 23.99 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 23.99. The average price that HROW shares were previous bought at was USD 28.6792. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in HROW has increased by USD 10,807 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 10.24 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 10.24. The average price that NRIX shares were previous bought at was USD 13.5726. The current market price is -24.6% lower than average price they were purchased at. The value of the holding in NRIX has increased by USD 15,585 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 7.23001 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 7.23001. The average price that NTLA shares were previous bought at was USD 8.89332. The current market price is -18.7% lower than average price they were purchased at. The value of the holding in NTLA has increased by USD 17,874 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.4 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.4. The average price that BCRX shares were previous bought at was USD 8.02161. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 18,085 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 7.30999 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 7.30999. The average price that OCUL shares were previous bought at was USD 7.29213. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in OCUL has increased by USD 10,275 compared to the previous valuation of Ocular Therapeutix Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 14.88 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 14.88. The average price that SPRY shares were previous bought at was USD 12.2049. The current market price is 21.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 6.83999 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 6.83999. The average price that DAWN shares were previous bought at was USD 9.29523. The current market price is -26.4% lower than average price they were purchased at. The value of the holding in DAWN has increased by USD 3,823 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 28.84 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 28.84. The average price that ZLAB shares were previous bought at was USD 34.5512. The current market price is -16.5% lower than average price they were purchased at. The value of the holding in ZLAB has fallen by USD 2,775 compared to the previous valuation of Zai Lab Ltd |
| XNCR - Xencor Inc | HOLD | 0 @ USD 9.7 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 9.7. The average price that XNCR shares were previous bought at was USD 15.8538. The current market price is -38.8% lower than average price they were purchased at. The value of the holding in XNCR has increased by USD 5,970 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 14.92 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 14.92. The average price that TVTX shares were previous bought at was USD 20.1564. The current market price is -26.0% lower than average price they were purchased at. The value of the holding in TVTX has increased by USD 14,931 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 6.33 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 6.33. The average price that RCKT shares were previous bought at was USD 8.44257. The current market price is -25.0% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 8,955 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 5.89999 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 5.89999. The average price that KURA shares were previous bought at was USD 7.77779. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in KURA has increased by USD 5,677 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 11.54 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 11.54. The average price that SNDX shares were previous bought at was USD 13.9319. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in SNDX has increased by USD 19,531 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6. The average price that NVAX shares were previous bought at was USD 7.46576. The current market price is -19.6% lower than average price they were purchased at. The value of the holding in NVAX has fallen by USD 15,018 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6. The average price that NVAX shares were previous bought at was USD 7.46576. The current market price is -19.6% lower than average price they were purchased at. The value of the holding in NVAX has fallen by USD 15,018 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 28.41 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 28.41. The average price that IMCR shares were previous bought at was USD 29.3471. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in IMCR has increased by USD 9,995 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 18.27 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 18.27. The average price that INVA shares were previous bought at was USD 17.6616. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in INVA has increased by USD 5,267 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 69.21 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 69.21. The average price that ANIP shares were previous bought at was USD 64.2378. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in ANIP has increased by USD 105 compared to the previous valuation of ANI Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 16.53 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 16.53. The average price that ELVN shares were previous bought at was USD 20.8097. The current market price is -20.6% lower than average price they were purchased at. The value of the holding in ELVN has increased by USD 10,537 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.5. The average price that VIR shares were previous bought at was USD 7.59316. The current market price is -27.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 4,200 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.5 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.5. The average price that VIR shares were previous bought at was USD 7.59316. The current market price is -27.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 4,200 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 8.02999 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 8.02999. The average price that AVDL shares were previous bought at was USD 8.50132. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in AVDL has fallen by USD 5,485 compared to the previous valuation of Avadel Pharmaceuticals PLC |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 11.53 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 11.53. The average price that ZYME shares were previous bought at was USD 12.9145. The current market price is -10.7% lower than average price they were purchased at. The value of the holding in ZYME has increased by USD 9,121 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 7.75 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 7.75. The average price that AUPH shares were previous bought at was USD 7.96447. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in AUPH has increased by USD 5,327 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 12.295 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 12.295. The average price that CNTA shares were previous bought at was USD 15.6955. The current market price is -21.7% lower than average price they were purchased at. The value of the holding in CNTA has increased by USD 20,522 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 13.01 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 13.01. The average price that ARQT shares were previous bought at was USD 15.145. The current market price is -14.1% lower than average price they were purchased at. The value of the holding in ARQT has increased by USD 2,840 compared to the previous valuation of Arcutis Biotherapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 4.37001 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 4.37001. The average price that COGT shares were previous bought at was USD 7.23079. The current market price is -39.6% lower than average price they were purchased at. The value of the holding in COGT has increased by USD 5,311 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 7.08 | USD 0 | |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 4.815 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 4.815. The average price that ARDX shares were previous bought at was USD 5.19956. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in ARDX has increased by USD 23,924 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 27.01 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 27.01. The average price that COLL shares were previous bought at was USD 29.855. The current market price is -9.5% lower than average price they were purchased at. The value of the holding in COLL has fallen by USD 152 compared to the previous valuation of Collegium Pharmaceutical Inc |
| ETNB - 89bio Inc | HOLD | 0 @ USD 6.06001 | USD 0 | The current share valuation price of ETNB based on adjusted close was USD 6.06001. The average price that ETNB shares were previous bought at was USD 8.6285. The current market price is -29.8% lower than average price they were purchased at. The value of the holding in ETNB has increased by USD 11,585 compared to the previous valuation of 89bio Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 20.21 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 20.21. The average price that KNSA shares were previous bought at was USD 21.9562. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in KNSA has fallen by USD 6,374 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| GMAB - Genmab AS | HOLD | 0 @ USD 20.04 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 20.04. The average price that GMAB shares were previous bought at was USD 19.8103. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in GMAB has increased by USD 9,716 compared to the previous valuation of Genmab AS however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 9.19999 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 9.19999. The average price that PRTA shares were previous bought at was USD 13.1099. The current market price is -29.8% lower than average price they were purchased at. The value of the holding in PRTA has fallen by USD 1,540 compared to the previous valuation of Prothena Corporation plc |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 7.89 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 7.89. The average price that CGEM shares were previous bought at was USD 8.64048. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in CGEM has increased by USD 7,995 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 21.51 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 21.51. The average price that CSTL shares were previous bought at was USD 22.0305. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in CSTL has increased by USD 3,417 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 7.32999 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 7.32999. The average price that ADPT shares were previous bought at was USD 8.16647. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in ADPT has fallen by USD 11,037 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 2.42 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 2.42. The average price that ABCL shares were previous bought at was USD 2.55619. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 4,221 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 7.39002 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 7.39002. The average price that BCYC shares were previous bought at was USD 10.0453. The current market price is -26.4% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 2,213 compared to the previous valuation of Bicycle Therapeutics Ltd |
| ERAS - Erasca Inc | HOLD | 0 @ USD 1.16 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 1.16. The average price that ERAS shares were previous bought at was USD 1.27531. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in ERAS has fallen by USD 1,416 compared to the previous valuation of Erasca Inc |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 7.995 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 7.995. The average price that REPL shares were previous bought at was USD 10.7898. The current market price is -25.9% lower than average price they were purchased at. The value of the holding in REPL has increased by USD 13,651 compared to the previous valuation of Replimune Group Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.46 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.46. The average price that PLRX shares were previous bought at was USD 2.48785. The current market price is -41.3% lower than average price they were purchased at. The value of the holding in PLRX has increased by USD 542 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 1.77 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 1.77. The average price that MRVI shares were previous bought at was USD 2.46776. The current market price is -28.3% lower than average price they were purchased at. The value of the holding in MRVI has increased by USD 3,644 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 2.69001 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 2.69001. The average price that RLAY shares were previous bought at was USD 3.64353. The current market price is -26.2% lower than average price they were purchased at. The value of the holding in RLAY has increased by USD 6,461 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 8.95 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 8.95. The average price that AVXL shares were previous bought at was USD 9.08831. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in AVXL has increased by USD 4,427 compared to the previous valuation of Anavex Life Sciences Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 10.79 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 10.79. The average price that EOLS shares were previous bought at was USD 13.263. The current market price is -18.6% lower than average price they were purchased at. The value of the holding in EOLS has increased by USD 20,383 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 24.65 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 24.65. The average price that PCRX shares were previous bought at was USD 24.9798. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in PCRX has increased by USD 3,890 compared to the previous valuation of Pacira BioSciences, Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 4.77 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 4.77. The average price that ORIC shares were previous bought at was USD 7.33248. The current market price is -34.9% lower than average price they were purchased at. The value of the holding in ORIC has increased by USD 2,702 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TRML - Tourmaline Bio Inc. | HOLD | 0 @ USD 16.01 | USD 0 | The current share valuation price of TRML based on adjusted close was USD 16.01. The average price that TRML shares were previous bought at was USD 15.9236. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in TRML has increased by USD 18,829 compared to the previous valuation of Tourmaline Bio Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 0.726694 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 0.726694. The average price that IRWD shares were previous bought at was USD 1.75739. The current market price is -58.6% lower than average price they were purchased at. The value of the holding in IRWD has fallen by USD 1,656 compared to the previous valuation of Ironwood Pharmaceuticals Inc |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 3.15 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 3.15. The average price that ABUS shares were previous bought at was USD 3.31738. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in ABUS has increased by USD 8,223 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.43 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.43. The average price that AUTL shares were previous bought at was USD 1.49201. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in AUTL has increased by USD 8,116 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 13.35 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 13.35. The average price that MLYS shares were previous bought at was USD 14.4876. The current market price is -7.9% lower than average price they were purchased at. The value of the holding in MLYS has fallen by USD 3,568 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock |
| CVAC - CureVac NV | HOLD | 0 @ USD 3.12 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 3.12. The average price that CVAC shares were previous bought at was USD 3.03888. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in CVAC has fallen by USD 8,606 compared to the previous valuation of CureVac NV |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 4.03001 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 4.03001. The average price that PHAT shares were previous bought at was USD 5.20294. The current market price is -22.5% lower than average price they were purchased at. The value of the holding in PHAT has fallen by USD 6,609 compared to the previous valuation of Phathom Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 20.55 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 20.55. The average price that ANAB shares were previous bought at was USD 16.9843. The current market price is 21.0% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 21,867 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 4.42 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 4.42. The average price that OLMA shares were previous bought at was USD 4.26056. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in OLMA has increased by USD 5,534 compared to the previous valuation of Olema Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.67999 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.67999. The average price that HUMA shares were previous bought at was USD 3.12398. The current market price is -46.2% lower than average price they were purchased at. The value of the holding in HUMA has increased by USD 7,540 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 5.15999 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 5.15999. The average price that THRD shares were previous bought at was USD 3.45714. The current market price is 49.3% higher than average price they were purchased at. The value of the holding in THRD has increased by USD 617 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 1.65 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 1.65. The average price that SANA shares were previous bought at was USD 2.32953. The current market price is -29.2% lower than average price they were purchased at. The value of the holding in SANA has increased by USD 7,283 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 3.01 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 3.01. The average price that SVRA shares were previous bought at was USD 2.77127. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in SVRA has increased by USD 6,422 compared to the previous valuation of Savara Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SLRN - ACELYRIN, INC. Common Stock | HOLD | 0 @ USD 2.2 | USD 0 | The current share valuation price of SLRN based on adjusted close was USD 2.2. The average price that SLRN shares were previous bought at was USD 2.45903. The current market price is -10.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of ACELYRIN, INC. Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 5.67501 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 5.67501. The average price that EYPT shares were previous bought at was USD 5.98649. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in EYPT has increased by USD 4,296 compared to the previous valuation of Eyepoint Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| YMAB - Y mAbs Therapeutics | HOLD | 0 @ USD 4.69002 | USD 0 | The current share valuation price of YMAB based on adjusted close was USD 4.69002. The average price that YMAB shares were previous bought at was USD 5.47715. The current market price is -14.4% lower than average price they were purchased at. The value of the holding in YMAB has increased by USD 2,936 compared to the previous valuation of Y mAbs Therapeutics however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.45 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.45. The average price that ALLO shares were previous bought at was USD 1.57974. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in ALLO has increased by USD 5,095 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.17 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.17. The average price that PACB shares were previous bought at was USD 1.30756. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in PACB has fallen by USD 4,128 compared to the previous valuation of Pacific Biosciences of California |
| ALEC - Alector Inc | HOLD | 0 @ USD 0.920099 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 0.920099. The average price that ALEC shares were previous bought at was USD 1.51985. The current market price is -39.5% lower than average price they were purchased at. The value of the holding in ALEC has fallen by USD 2,880 compared to the previous valuation of Alector Inc |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 24.66 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 24.66. The average price that GLPG shares were previous bought at was USD 25.5403. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,138 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 24.66 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 24.66. The average price that GLPG shares were previous bought at was USD 25.5403. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,138 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 13.76 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 13.76. The average price that HCM shares were previous bought at was USD 14.8118. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 298 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 13.76 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 13.76. The average price that HCM shares were previous bought at was USD 14.8118. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 298 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 17.29 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 17.29. The average price that PAHC shares were previous bought at was USD 23.0749. The current market price is -25.1% lower than average price they were purchased at. The value of the holding in PAHC has increased by USD 4,633 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 10.53 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 10.53. The average price that ARCT shares were previous bought at was USD 13.1815. The current market price is -20.1% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 3,065 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.79 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.79. The average price that OABI shares were previous bought at was USD 3.22093. The current market price is -44.4% lower than average price they were purchased at. The value of the holding in OABI has increased by USD 1,147 compared to the previous valuation of OmniAb Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 5.99001 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 5.99001. The average price that SIGA shares were previous bought at was USD 5.57068. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in SIGA has increased by USD 2,503 compared to the previous valuation of SIGA Technologies Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 9.67001 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 9.67001. The average price that URGN shares were previous bought at was USD 10.5329. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in URGN has fallen by USD 14,719 compared to the previous valuation of UroGen Pharma Ltd |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 1.24 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 1.24. The average price that PRME shares were previous bought at was USD 2.27886. The current market price is -45.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Prime Medicine, Inc. Common Stock |
| VERV - Verve Therapeutics Inc | HOLD | 0 @ USD 4.59001 | USD 0 | The current share valuation price of VERV based on adjusted close was USD 4.59001. The average price that VERV shares were previous bought at was USD 5.86434. The current market price is -21.7% lower than average price they were purchased at. The value of the holding in VERV has increased by USD 3,456 compared to the previous valuation of Verve Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 5.93999 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 5.93999. The average price that RGNX shares were previous bought at was USD 7.95621. The current market price is -25.3% lower than average price they were purchased at. The value of the holding in RGNX has fallen by USD 5,408 compared to the previous valuation of Regenxbio Inc |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 1.24 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 1.24. The average price that TSHA shares were previous bought at was USD 1.59326. The current market price is -22.2% lower than average price they were purchased at. The value of the holding in TSHA has increased by USD 5,471 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 5.40999 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 5.40999. The average price that MGTX shares were previous bought at was USD 7.16364. The current market price is -24.5% lower than average price they were purchased at. The value of the holding in MGTX has increased by USD 3,321 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 2.4 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 2.4. The average price that TERN shares were previous bought at was USD 5.04458. The current market price is -52.4% lower than average price they were purchased at. The value of the holding in TERN has increased by USD 6,152 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 12 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 12. The average price that KALV shares were previous bought at was USD 11.2332. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in KALV has increased by USD 5,945 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 27 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 27. The average price that GRAL shares were previous bought at was USD 33.5884. The current market price is -19.6% lower than average price they were purchased at. The value of the holding in GRAL has increased by USD 7,984 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 4.10999 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 4.10999. The average price that XERS shares were previous bought at was USD 5.20022. The current market price is -21.0% lower than average price they were purchased at. The value of the holding in XERS has increased by USD 2,087 compared to the previous valuation of Xeris Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 0.509801 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 0.509801. The average price that LXRX shares were previous bought at was USD 0.633415. The current market price is -19.5% lower than average price they were purchased at. The value of the holding in LXRX has increased by USD 1,725 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 8.62001 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 8.62001. The average price that TBPH shares were previous bought at was USD 9.14073. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in TBPH has increased by USD 576 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 3.06 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 3.06. The average price that FDMT shares were previous bought at was USD 4.14786. The current market price is -26.2% lower than average price they were purchased at. The value of the holding in FDMT has increased by USD 3,087 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 3.98001 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 3.98001. The average price that AMLX shares were previous bought at was USD 3.60636. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 6,388 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 3.15998 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 3.15998. The average price that VYGR shares were previous bought at was USD 4.00715. The current market price is -21.1% lower than average price they were purchased at. The value of the holding in VYGR has increased by USD 717 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 2.61001 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 2.61001. The average price that MXCT shares were previous bought at was USD 3.64563. The current market price is -28.4% lower than average price they were purchased at. The value of the holding in MXCT has increased by USD 2,988 compared to the previous valuation of MaxCyte Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ITOS - Iteos Therapeutics Inc | HOLD | 0 @ USD 6.50999 | USD 0 | The current share valuation price of ITOS based on adjusted close was USD 6.50999. The average price that ITOS shares were previous bought at was USD 6.73571. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in ITOS has increased by USD 4,617 compared to the previous valuation of Iteos Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 1.28999 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 1.28999. The average price that TNGX shares were previous bought at was USD 2.12053. The current market price is -39.2% lower than average price they were purchased at. The value of the holding in TNGX has increased by USD 520 compared to the previous valuation of Tango Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SAGE - Sage Therapeutic | HOLD | 0 @ USD 7.43001 | USD 0 | The current share valuation price of SAGE based on adjusted close was USD 7.43001. The average price that SAGE shares were previous bought at was USD 7.39975. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in SAGE has increased by USD 1,732 compared to the previous valuation of Sage Therapeutic however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.33001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.33001. The average price that VNDA shares were previous bought at was USD 4.73532. The current market price is -8.6% lower than average price they were purchased at. The value of the holding in VNDA has fallen by USD 1,192 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 0.433599 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 0.433599. The average price that LYEL shares were previous bought at was USD 0.551117. The current market price is -21.3% lower than average price they were purchased at. The value of the holding in LYEL has fallen by USD 688 compared to the previous valuation of Lyell Immunopharma Inc |
| QURE - Uniqure NV | HOLD | 0 @ USD 13 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 13. The average price that QURE shares were previous bought at was USD 13.2992. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in QURE has increased by USD 91,069 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 1.47999 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 1.47999. The average price that ACIU shares were previous bought at was USD 2.35286. The current market price is -37.1% lower than average price they were purchased at. The value of the holding in ACIU has fallen by USD 930 compared to the previous valuation of AC Immune Ltd |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.69002 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.69002. The average price that BMEA shares were previous bought at was USD 2.99801. The current market price is -43.6% lower than average price they were purchased at. The value of the holding in BMEA has increased by USD 1,754 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 2.96999 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 2.96999. The average price that AVIR shares were previous bought at was USD 3.00572. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in AVIR has fallen by USD 1,171 compared to the previous valuation of Atea Pharmaceuticals Inc |
| PGEN - Precigen Inc | HOLD | 0 @ USD 1.39 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 1.39. The average price that PGEN shares were previous bought at was USD 1.77135. The current market price is -21.5% lower than average price they were purchased at. The value of the holding in PGEN has increased by USD 2,849 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.26001 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.26001. The average price that MGNX shares were previous bought at was USD 2.09808. The current market price is -39.9% lower than average price they were purchased at. The value of the holding in MGNX has increased by USD 2,294 compared to the previous valuation of MacroGenics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 1.28001 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 1.28001. The average price that EDIT shares were previous bought at was USD 1.27428. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in EDIT has increased by USD 382 compared to the previous valuation of Editas Medicine Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| OKUR - OKUR | HOLD | 0 @ USD 2.88992 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 2.88992. The average price that OKUR shares were previous bought at was USD 8.04583. The current market price is -64.1% lower than average price they were purchased at. The value of the holding in OKUR has fallen by USD 225 compared to the previous valuation of OKUR |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 7.36 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 7.36. The average price that AMRX shares were previous bought at was USD 8.34948. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in AMRX has increased by USD 26,526 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 20.64 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 20.64. The average price that CGON shares were previous bought at was USD 26.1973. The current market price is -21.2% lower than average price they were purchased at. The value of the holding in CGON has increased by USD 15,307 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 7.50999 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 7.50999. The average price that TXG shares were previous bought at was USD 10.5756. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in TXG has fallen by USD 26,275 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 7.50999 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 7.50999. The average price that TXG shares were previous bought at was USD 10.5756. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in TXG has fallen by USD 26,275 compared to the previous valuation of Terex Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 33.79 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 33.79. The average price that PRAX shares were previous bought at was USD 45.133. The current market price is -25.1% lower than average price they were purchased at. The value of the holding in PRAX has increased by USD 37,342 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 12.67 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 12.67. The average price that SYRE shares were previous bought at was USD 18.9041. The current market price is -33.0% lower than average price they were purchased at. The value of the holding in SYRE has increased by USD 7,031 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 8.12998 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 8.12998. The average price that TRDA shares were previous bought at was USD 9.40474. The current market price is -13.6% lower than average price they were purchased at. The value of the holding in TRDA has increased by USD 5,145 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| CRGX - CARGO Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 4.64002 | USD 0 | The current share valuation price of CRGX based on adjusted close was USD 4.64002. The average price that CRGX shares were previous bought at was USD 3.77286. The current market price is 23.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of CARGO Therapeutics, Inc. Common Stock however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 7.69001 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 7.69001. The average price that STOK shares were previous bought at was USD 8.35516. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in STOK has increased by USD 3,411 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 4.54999 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 4.54999. The average price that ALT shares were previous bought at was USD 5.78947. The current market price is -21.4% lower than average price they were purchased at. The value of the holding in ALT has increased by USD 5,382 compared to the previous valuation of Altitude Group Plc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 5.77 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 5.77. The average price that MNMD shares were previous bought at was USD 6.89928. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in MNMD has increased by USD 11,245 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.10999 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.10999. The average price that FATE shares were previous bought at was USD 1.09917. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in FATE has increased by USD 3,041 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 0.354709 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 0.354709. The average price that MRSN shares were previous bought at was USD 0.53763. The current market price is -34.0% lower than average price they were purchased at. The value of the holding in MRSN has increased by USD 1,039 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-04-17 this would crystalise an overall loss. |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.524613 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.524613. The average price that STRO shares were previous bought at was USD 1.35795. The current market price is -61.4% lower than average price they were purchased at. The value of the holding in STRO has fallen by USD 565 compared to the previous valuation of Sutro Biopharma |